Inotropic Therapy for Heart Failure with Reduced Ejection Fraction in Patients with Atrial Fibrillation History

First-Line Management of HFrEF with History of AFib

The European Society of Cardiology recommends that ACE inhibitors (or ARBs if intolerant) plus beta-blockers form the foundation of HFrEF treatment, with the addition of mineralocorticoid receptor antagonists (MRAs) for patients who remain symptomatic despite ACE-I and beta-blocker therapy, for patients with heart failure with reduced ejection fraction (HFrEF) and history of atrial fibrillation (AFib) 2, 3
Diuretics should be used for symptom relief in patients with fluid retention, according to the American Heart Association, for patients with HFrEF and history of AFib 4
A rhythm control strategy is reasonable (Class IIa) for patients with AFib history, as recommended by the American College of Cardiology 5

Inotropic therapy should be reserved for patients with low cardiac output states, presence of signs of hypoperfusion, and evidence of congestion despite vasodilators and/or diuretics, as indicated by the European Society of Cardiology, for patients with HFrEF and history of AFib 1

Dobutamine is the preferred inotropic agent for short-term treatment, with a dosing regimen of 2-3 μg/kg/min without loading dose, titrated up to 15 μg/kg/min based on clinical response, as recommended by the European Society of Cardiology, for patients with HFrEF and history of AFib 1
Dopamine is an alternative inotropic agent, with a dosing regimen of 3-5 μg/kg/min for inotropic effect, and higher doses (>5 μg/kg/min) providing both inotropic and vasopressor effects, as indicated by the European Society of Cardiology, for patients with HFrEF and history of AFib 1

Inotropic support should be administered as early as possible when needed and withdrawn as soon as adequate organ perfusion is restored, as recommended by the European Society of Cardiology, for patients with HFrEF and history of AFib 1
Continuous clinical monitoring and ECG telemetry is required due to increased risk of arrhythmias, as indicated by the European Society of Cardiology, for patients with HFrEF and history of AFib 1

Gradual tapering of inotropic support is essential, with a decrease in dobutamine by steps of 2 μg/kg/min, as recommended by the European Society of Cardiology, for patients with HFrEF and history of AFib 1
Simultaneous optimization of oral heart failure therapy is necessary, as indicated by the European Society of Cardiology, for patients with HFrEF and history of AFib 1
Consideration of device therapy (ICD, CRT) is recommended for eligible patients after stabilization, as indicated by the European Society of Cardiology, for patients with HFrEF and history of AFib 2, 3